TeaM O. KUNDUZOVA / A. PARINI

Cardiometabolic remodeling : mechanisms and microenvironnement (CERAMIC)

 

The focus of our research program is to delineate the molecular mechanisms that govern cardiac remodeling processes and to translate these discoveries into new diagnostic and therapeutic strategies for heart failure (HF). Fibrosis, inflammation and metabolic abnormalities are major aspects of cardiac remodeling and ventricular dysfunction leading to the development and progression of HF. This is currently the central axis of our research projects that combine the expertise of clinical and academic researchers. A specific focus of our studies is to understand how metabolism regulates myocyte and stroma cell functions and how to exploit metabolic changes for therapeutic benefits to prevent adverse cardiac remodeling. We combine state-of-the-art « omics » technologies with mainstay techniques of molecular biology, cell biology, biochemistry, (patho)physiology and pharmacology to identify and characterize new actors and networks in cardiovascular biology. The translational research programs of our team foster the multidisciplinary integration of basic- and patient-oriented research, moving from bench to bedside.

TEAM

 
Tous / AllTeam leaderResearchersCliniciansStudentsPost Doctoral fellowsTechnical staff
Responsable d'équipe

Oxana KUNDUZOVA

Co-responsable d'équipe

Angelo PARINI

Chercheur

Frédéric BOAL

Chercheuse

Nathalie PIZZINAT

Chercheuse

Véréna POINSOT

Chercheuse

Hélène TRONCHERE

Enseignant-Chercheur

Daniel CUSSAC

Associate profesor

Yannis SAINTE-MARIE

Clinician

Jérôme RONCALLI

Clinicienne

Charlotte ROUZAUD LABORDE

Clinicienne

Frédérique SAVAGNER

Kévin CHANDRESHWAR

Vanessa NADER

Doctorante

Salwa SOUSSI

Virginie JACQUES
PhD student

Virginie JACQUES

Dimitri MARSAL
Technician

Dimitri MARSAL

Technician

Sabrina BENAOUADI

Sourour BEN HARZALLAH

Thoria DIAB

Solomiia KRAMAR

Lesia SAVCHENKO

Oksana BATKIVSKA

Ryeonshi KANG

Engineer

Audrey SWIADER

Responsable d'équipe

Oxana KUNDUZOVA

Co-responsable d'équipe

Angelo PARINI

Chercheur

Frédéric BOAL

:frederic.boal@inserm.fr

Tél/Phone:+33(0)5 31 22 41 17

Chercheuse

Nathalie PIZZINAT

Chercheuse

Véréna POINSOT

Chercheuse

Hélène TRONCHERE

Enseignant-Chercheur

Daniel CUSSAC

Associate profesor

Yannis SAINTE-MARIE

Associate Professor in physiology at the Faculty of Pharmaceuticals sciences, Toulouse

In vivo studies, in preclinical models, of cardiac remodeling associated with various cardiac pathologies, of its molecular actors and of the means of intervention on the identified therapeutic targets.

Career path
Yannis Sainte-Marie has a PhD in Biology from the Paris VII University, France, in 2006 for his work on new roles for the mineralocorticoid receptor in physiopathology. After a post-doctoral project on molecular actor of heart failure, he was recruited as assistant professor in Physiology at the Faculty of Pharmaceuticals sciences and joined the team in 2010.

Main domains of expertise
Cardiac physiopathology, animal model design and phenotypic characterization.

Clinician

Jérôme RONCALLI

Clinicienne

Charlotte ROUZAUD LABORDE

Clinicienne

Frédérique SAVAGNER

Kévin CHANDRESHWAR

Vanessa NADER

Doctorante

Salwa SOUSSI

PhD student

Virginie JACQUES

Technician

Dimitri MARSAL

Technician

Sabrina BENAOUADI

Sourour BEN HARZALLAH

Thoria DIAB

Solomiia KRAMAR

Lesia SAVCHENKO

Oksana BATKIVSKA

Ryeonshi KANG

Engineer

Audrey SWIADER

Engineer INSERM

Expert in Cell biology and imaging technics. She develops tools allowing the study of signaling pathways on cultured vascular cells and tissues.

Career path
Master’s degree in cell biology and physiology (2003-2004). Hired at Paul Sabatier University in 2005 and at INSERM in 2012.

Main domains of expertise
Signalisation, Biologie cellulaire et moléculaire, Imagerie, Cytométrie en flux

Metabolic reprogramming of stromal cells in cardiac remodeling and impact on the inflammatory microenvironment

 

 

Coordinators : O. Kunduzova, F. Savagner, V. Poinsot, D. Cussac, A. Parini

Through our research program we aim to characterize the metabolic reprogramming of fibroblast-to-myofibroblast transition in myocardial fibrotic remodeling, to define the metabolic profile of cardiac mesenchymal stromal cells in relation to their secretory activities and to establish their links with immunoinflammatory cells in HF predisposing conditions (pressure overload, obesity, aging).

Phosphoinositides metabolism in cardiac remodeling

 

 

Coordinators : F. Boal, H. Tronchère, O. Kunduzova

Our research focuses on the role of the rare phosphoinositide phosphatidylinositol 5-phosphate (PI5P) in cardiac remodeling. More specifically, we aim to decipher the involvement of its biosynthetic pathways in fibrotic and cardiometabolic remodeling. In particular, we investigate the role of the lipid kinase PIKfyve and the phosphatase myotubularin MTM1 in cardiomyocytes metabolic alterations and activation of cardiac fibroblasts during the progression of heart failure.

Translation to clinical research

 

Coordinators : J. Roncalli, C. Laborde, A. Parini

The translational part of our project concerns two major Axes: 1) the design of novel strategies targeting at challenges of cardiac regenerative medicine and 2) the identification of novel therapeutic targets and biomarkers of cardiac dysfunction associated with obesity and aging. Our group has a large experience on the approaches of cardiac cell therapy using bone marrow mesenchymal stem cells  (BM-MSCs). In addition, we have developed an alternative strategy based on the design of bioengineered BM-MSCs/biomatrices providing the local delivery of beneficial paracrine factors without major side effects related to intramyocardial injection.

 Selected publications

Apilimod alters TGFβ signaling pathway and prevents cardiac fibrotic remodeling. Cinato M, Guitou L, Saidi A, Timotin A, Sperazza E, Duparc T, Zolov SN, Giridharan SSP, Weisman LS, Martinez LO, Roncalli J, Kunduzova O, Tronchere H, Boal F. Theranostic. 2021. Pubmed

Galanin promotes autophagy and alleviates apoptosis in the hypertrophied heart through FoxO1 pathway. Martinelli I, Timotin A, Moreno-Corchado P, Marsal D, Kramar S, Loy H, Joffre C, Boal F, Tronchere H,  Kunduzova O. Redox Biol. 2021. Pubmed

Local production of tenascin-C acts as a trigger for monocyte/macrophage recruitment that provokes cardiac dysfunction. Abbadi D , Laroumanie F, Bizou M, Pozzo J, Daviaud D, Delage D, Calise D, Gaits-Iacovoni F, Dutaur M, Tortosa F, Renaud-Gabardos E , Douin-Echinard V, Prats A.C, Roncalli J, Parini A, and Pizzinat N. Cardiovasc Res. 2018. Pubmed

Surfing the clinical trials of mesenchymal stem cell therapy in ischemic cardiomyopathy. Razeghian-Jahromi I, Matta A.G, Canitrot R, Javad Zibaeenezhad M, Razmkhah M, Safari A, Nader V, Roncalli J. Stem Cell Res ther. 2021. Pubmed

Aging induces cardiac mesenchymal stromal cell senescence and promotes endothelial cell fate of the CD90 + subset. Martini H, Iacovoni J.S, Maggiorani D, Dutaur M, Marsal D.J, Roncalli J, Itier R, Dambrin C, Pizzinat N, Mialet‐Perez J, Cussac D, Parini A, Lefevre L, Douin‐Echinard V. Aging Cell. 2019. Pubmed

FUNDINGS

logotype i2mc
logotype i2mc

Inserm/UPS UMR 1297 - I2MC Institut des Maladies Métaboliques et Cardiovasculaires

1 avenue Jean Poulhès - BP 84225 - 31432 Toulouse Cedex 4

Tél. : 05 61 32 56 00

Contactez-nous

 

Horaires

Du lundi au vendredi
8h30 - 12h30 / 13h45 -16h45